INOTREM
Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today that it has filed a patent to protect a new therapeutic modality against TREM-1, a monoclonal antibody.
The filing of this monoclonal antibody patent is a significant milestone for Inotrem’s strategic development as it represents the company’s second asset, next to nangibotide, and a further diversification of its drug portfolio. Moreover, by modulating the activity of the TREM-1 pathway over extended periods of time, this therapeutic modality offers a new and promising alternative for the treatment of chronic inflammatory diseases.
TREM-1 is an immunoreceptor initially discovered for its role in the pathophysiology of acute inflammatory syndromes and in particular septic shock. Since its inception in 2013, Inotrem has introduced the therapeutic peptide nangibotide into the clinics for acute inflammatory syndromes secondary to severe infections. Two Phase IIB clinical trials are currently ongoing in septic shock and COVID-19 patients. Since its discovery in 2000, an increasing number of research work indicated the implication of the therapeutic target TREM-1 in not only acute inflammatory diseases but also in the development of chronic inflammation. Pioneering these approaches, Inotrem initiated in 2019 a proprietary research and discovery program to identify a new modality against TREM-1 in the form of a therapeutic monoclonal antibody, with pharmacological properties suitable for the management of chronic indications.
“Inotrem’s research team’s exceptional commitment is at the core of today’s success. Adding a monoclonal antibody to our therapeutic modalities targeting the TREM-1 pathway now allows us to expand our development efforts beyond the current acute indications to also address chronic inflammatory syndromes with a high unmet medical need,” said Marc Derive, co-founder and Chief Scientific Officer of Inotrem.
“Today’s announcement constitutes a key advancement for Inotrem. This new patent application demonstrates the company’s ability to deploy its vision and strategy. Through its proprietary technology platform addressing inflammatory diseases, it has the potential to develop treatments in a wide number of inflammatory indications, both acute and now chronic, for which there are today no or limited specific treatment. We are looking forward to the clinical development progress of this new asset, with preclinical development slated to start later this year,” said Jean-Jacques Garaud, Executive Vice-President, Head of Scientific and Medical Affairs and Inotrem’s co-founder.
Chronic inflammatory diseases are inflammatory-driven diseases of the digestive system, joints, skin, respiratory system, kidneys, and various other organs. Most of them have no cure, and new biologics have recently reached the market to target inflammation. But there are still a high number of non-responders to these innovative drugs, and therefore a very significant unmet medical need.
About Inotrem
Inotrem S.A. is an advanced clinical stage biotech company specialized in immunotherapy for inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. Through its proprietary technology platform, Inotrem has developed the first-in-class TREM-1 inhibitor, nangibotide, with potential applications in a number of therapeutic indications such as septic shock and COVID-19. In parallel, Inotrem has launched a program to develop new therapeutic modalities targeting chronic inflammatory diseases. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors. For more information please visit: www.inotrem.com
About TREM-1 pathway
TREM-1 pathway is an amplification loop of the immune response that triggers an exuberant and hyperactivated immune state which is known to play a crucial role in the pathophysiology of septic shock and acute myocardial infarction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210622005982/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
PPG introduces PPG MIX‘N’SHAKE automated stirring technology for body shops14.10.2025 08:30:00 CEST | Press release
System improves productivity, reduces waste, enhances color accuracy PPG (NYSE: PPG) today announced the introduction of PPG MIX‘N’SHAKE™ automated stirring technology designed to eliminate traditional manual stirring methods in the automotive refinish industry. The system, which is available globally, improves paint mix consistency, reduces consumable waste and saves time for painters and body shops. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013065453/en/ PPG MIX’N’SHAKE™ automated stirring technology replaces manual stirring processes to ensure a homogenized paint mix, complete color accuracy, and a better workplace. The PPG Mix‘n’Shake system will debut at the EQUIP AUTO trade show in Paris taking place Oct. 14-18. PPG will also showcase its PPG LINQ™ digital ecosystem, which is a finalist for the prestigious EQUIP AUTO Innovation Award. Because the PPG Mix‘n’Shake system eliminates manual stirring, it ensures con
Glesys to Acquire Verne’s Managed Private Cloud Operations and Two Data Centers in Finland14.10.2025 08:00:00 CEST | Press release
Verne, the leading provider of low-carbon high-performance data centers across the Nordics, has today announced that Glesys, a leading Nordic provider of cloud and IaaS services, will acquire Verne’s managed private cloud operations in Finland, including data center facilities in Pori and Tampere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251006898290/en/ Pori Data Center Tunnel Corridor The agreement reflects both companies’ strategic priorities: for Glesys, it represents an important step in expanding its cloud and IaaS services, strengthening its position as a market leader in the Nordics and enhancing its capacity to deliver secure, energy-efficient and scalable solutions in the region. For Verne, it supports a sharpened focus on delivering low-carbon, high-performance colocation for AI and enterprise workloads, including its expansion plans in Mäntsälä, announced earlier this year. Glesys and Verne will continue to
Avanzanite Expands Italian Operations with General Manager Appointment14.10.2025 07:30:00 CEST | Press release
Giovanni Galliano joins Avanzanite having led 12 orphan medicine launches in Italy and overseen operations with more than €100 million in annual revenue. Avanzanite initiates engagement with the Italian rare blood disorder community who include the largest number of thalassemia patients in Europe. Avanzanite’s Q3 2025 revenues are 20% higher than Q2 2025, marking the strongest quarter to date. Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, announced today the appointment of Giovanni Galliano as General Manager for Italy. As the seventh executive leadership hire in 2025, this appointment further strengthens Avanzanite’s “Champions League” team of now more than 60 pharma professionals, while expanding operations into the European Union's third-largest economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013986565/en/ Giovanni Galliano, th
The Estée Lauder Companies Opens Global Fragrance Atelier in Paris, Accelerating Next-Generation Innovation in Perfume Artistry14.10.2025 07:00:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL), under the High Patronage of Mr. Emmanuel Macron, President of the French Republic,today announced the opening of its Fragrance Atelier within its new La Maison des Parfums on Rue Volney in Paris. This newly established global innovation hub is fully dedicated to world-class fragrance expertise, advanced technologies and cutting-edge capabilities, and will accelerate the company’s strategic ambitions in luxury and prestige fragrances. Rooted in the legacy of Mrs. Estée Lauder’s pioneering vision and her lifelong passion for fragrance, the Atelier’s opening marks a significant milestone in the company’s longstanding commitment to fragrance excellence and craftsmanship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013447078/en/ The Exterior of La Maison des Parfums “It is with great pride and excitement that we open our Fragrance Atelier in Paris,” said Stéphane de La Faverie, Pre
Ant International’s WorldFirst Launches in Thailand to Offer Unified Global Account Service for Thai SMEs14.10.2025 06:43:00 CEST | Press release
WorldFirst has officially launched in Thailand through the partnership with 2C2P, offering Thai SMEs the innovative unified global account service to simplify international transactions and fuel expansion.The Thai launch expands WorldFirst’s investment in Asia Pacific where its services are available to support businesses in China, Hong Kong SAR, Australia, New Zealand and Singapore. Ant International’s WorldFirst, an all-in-one digital cross-border payment and treasury account service for global businesses, announced the official launch in Thailand at its Bangkok Global Voyage event. It will provide Thai SMEs with efficient and secure global account service to simplify international payments and fuel their expansion. The offerings are delivered through the partnership with 2C2P and its subsidiary 2C2P Plus, a Southeast Asia-based payments provider licensed by the Bank of Thailand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/hom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom